Jaguar Health CFO Resigns, Interim Appointed
Ticker: JAGX · Form: 8-K · Filed: 2024-06-26T00:00:00.000Z
Sentiment: neutral
Topics: management-change, cfo, filing
TL;DR
Jaguar Health CFO out, interim in. Financials and exhibits filed.
AI Summary
On June 25, 2024, Jaguar Health, Inc. filed an 8-K report detailing the resignation of its Chief Financial Officer, Arthur J. Sim. The company also announced the appointment of Robert L. Smith as interim CFO. Additionally, the filing includes financial statements and exhibits.
Why It Matters
A change in CFO can signal shifts in financial strategy or stability, impacting investor confidence and the company's financial reporting.
Risk Assessment
Risk Level: medium — CFO changes can introduce uncertainty regarding financial management and future performance.
Key Players & Entities
- Jaguar Health, Inc. (company) — Registrant
- Arthur J. Sim (person) — Resigned Chief Financial Officer
- Robert L. Smith (person) — Interim Chief Financial Officer
- June 25, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the interim Chief Financial Officer of Jaguar Health, Inc.?
Robert L. Smith has been appointed as the interim Chief Financial Officer.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 25, 2024.
What was the former name of Jaguar Health, Inc.?
The former name was Jaguar Animal Health, Inc.
What is the Standard Industrial Classification for Jaguar Health, Inc.?
The SIC code is 2834, Pharmaceutical Preparations.
What items are included in this 8-K filing besides the Other Events?
The filing also includes Financial Statements and Exhibits.
Filing Stats: 517 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-06-26 08:30:29
Key Financial Figures
- $0.0001 — h registered Common Stock, Par Value $0.0001 Per Share JAGX The Nasdaq Capital Mar
- $1.00 — consecutive business days was below the $1.00 per share minimum required for continue
Filing Documents
- tm2418261d1_8k.htm (8-K) — 24KB
- tm2418261d1_ex99-1.htm (EX-99.1) — 11KB
- tm2418261d1_ex99-1img01.jpg (GRAPHIC) — 11KB
- 0001104659-24-074995.txt ( ) — 223KB
- jagx-20240625.xsd (EX-101.SCH) — 3KB
- jagx-20240625_lab.xml (EX-101.LAB) — 33KB
- jagx-20240625_pre.xml (EX-101.PRE) — 22KB
- tm2418261d1_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. As previously reported in its Current Report on Form 8-K filed on May 12, 2023, Jaguar Health, Inc. (the "Company") received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the closing bid price for the Company's common stock for the last 30 consecutive business days was below the $1.00 per share minimum required for continued listing under Nasdaq Listing Rule 5550(a)(2). On June 25, 2024, the Company received a letter from the Nasdaq Office of General Counsel notifying the Company that the minimum bid price deficiency had been cured and that Nasdaq had determined to continue the listing of the Company's common stock on The Nasdaq Stock Market. On June 26, 2024, the Company issued a press release with respect to the foregoing, a copy of which is furnished as Exhibit 99.1 hereto.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated June 26, 2024. 104 Cover Page Interactive Data File (embedded with the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAGUAR HEALTH, INC. By: /s/ Lisa A. Conte Name: Lisa A. Conte Title: Chief Executive Officer & President Date: June 26, 2024